Navigation Links
Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings
Date:11/15/2012

? 153.1.4 Insulin and Insulin Analogs 163.1.5 Monoclonal Antibodies 193.1.6 TNF-? Inhibitors 203.2 Promising Drug Classes for Biobetter Therapies 213.2.1 Human Growth Hormone 213.3 Comparison of Biosimilars and Biobetters 234 Technology Analysis 264.1 Introduction 264.1.1 Host Cell 264.1.2 Glycosylation 274.1.3 PEGylation 284.1.4 Polysialylation 284.1.5 Fusion Protein 284.1.6 PASylation 284.1.7 HESylation 295 Challenges and Opportunities 305.1 Opportunities 305.1.1 Biobetter Therapies Gain Substantial Market Shares upon Launch 305.1.2 Higher Success Rates in the Development of Biobetter Therapies 305.2 Challenges 305.2.1 Uncertainty Surrounding the Implementation of the Affordable Care Act will Limit Patient Access to Biobetter Drugs 305.2.2 Growing Debts and the Slowing of the Economy will Drive Governmental Bodies and Healthcare Providers to Restrict the Use of Expensive Biobetter Therapies 315.2.3 Regulatory Policies in Emerging Economies such as China and India do not Provide Enough Protection for the Development of Biobetter Therapies 316 Pipeline Analysis 326.1 Introduction3 326.2 Human Growth Hormone 326.3 Erythropoietin 346.4 Granulocyte-colony Stimulating Factor 356.5 Interferon-? and Interferon-? 366.6 Insulin and Insulin Analogs 386.7 Monoclonal Antibodies 406.8 Promising Drugs 426.8.1 LB03002 - HGH 426.8.2 Degludec - Insulin Analog 426.8.3 Theracim - Monoclonal Antibody 436.8.4 Pertuzumab - Monoclonal Antibody 436.8.5 RG7159 - Monoclonal Antibody 447 The US Regulatory Environment and Approval Pathways 457.1 Introduction 457.2 Biobetter Therapies 457.3 Biosimilar Therapies 468 The EU Regulatory Environment and Approval Pathways 478.1 Introduction 478.2 Biobetter Therapies 478.3 Biosimilar Therapies 479 Japan Regulatory Environment and Approval Pathways 499.1 Biobetter Therapies 499.2 Biosimilar Therapies 5010 Australia Regulatory Environment and Approval Pathways 5110.1 Biobetter Therapies 5110.2 Biosimilar Therapies 5111 China Regulatory Environment and
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference
2. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
3. Regulus to Present at the Lazard Capital Markets Healthcare Conference
4. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
5. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
6. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
7. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
8. Kinase Inhibitors: Global Markets -- Focus on the U.S.
9. MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 2017
10. MarketsandMarkets: Global Spine Surgery Devices Market Worth $14.8 Billion by 2017
11. MarketsandMarkets: World Sensors Market in Healthcare Applications is expected to reach $13.11 billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
(Date:9/16/2014)... East Longmeadow, MA (PRWEB) September 16, 2014 ... the appointment of Brian Highley as CEO of CIRTEC. ... at this exciting point for the Company.” noted Brian ... and operational performance while sustaining strong organic growth over ... accelerate CIRTEC’s growth by continuing to improve and expand ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... September 16, 2014 Convoy Therapeutics, ... and effective products to treat patients directly at ... a proprietary SPACE™ Technology Platform announced today that ... will present at the White Hat Life Science ... Hyatt Regency Phoenix. In addition, interested individuals ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... 19, 2012 RayBiotech, Inc. today announced that it ... core facilities at academic and government research institutes in ... the partnership program, core diagnostics facilities will be able ... component of their current services offerings at no cost ...
... 19, 2012  New data presented today studied the ... nitric oxide (NO) to patients being evaluated for ... privately held, advanced development-stage technology company, announced that ... Right Heart Catheterization (RHC) in subjects being evaluated ...
... Childhood obesity is a widespread global epidemic ... (NAFLD) [2] is now the leading cause of liver ... Liver Congress™ 2012 furthers this concern by showing that childhood ... the most common form of liver cancer [3] - ...
Cached Biology Technology:RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 2Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 3Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 4
(Date:9/16/2014)... The fire is human-caused and is still under ... and is mostly being fueled by grass and timber. ... to higher humidity. Yesterday (8/15), firefighters made progress ... fireline on the West and North sides of the fire. ... 7 20-person Crews, 4 Hot Shot Crews, 1 large Type ...
(Date:9/16/2014)... -- Each tree species has its own bacterial identity. ... colleagues from other institutions who studied the genetic fingerprints ... a Panamanian island. , "This study demonstrates for the ... and with different ecological strategies possess very different microbial ... Kembel, a former postdoctoral researcher in the UO,s Institute ...
(Date:9/16/2014)... new school year, a new football season and another ... September, SpaceX,s Dragon spacecraft is scheduled to blast off ... part of the company,s fourth contracted mission to the ... third suite of research investigations sponsored by the Center ... the role of managing the U.S. National Laboratory on ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... Humans and animals are able to perceive even the ... channels play a crucial role in the mediation of ... membrane which are highly responsive to external signals. Mechanosensitive ... ions (electrically charged particles), to cross the cell membrane, ...
... oil and gas concessions threatens the megadiverse Peruvian Amazon. ... reach around 70% of the region, threatening biodiversity and ... from a pair of researchers from the Institut de ... Barcelona (UAB), and the Washington DC-based NGO Save America,s ...
... and THE HAGUE, The Netherlands -- Recognizing the ... relationship and become recognized research leaders in the ... security, Stevens Institute of Technology recently entered into ... A Memorandum of Understanding (MOU) between the university ...
Cached Biology News:MDC researchers link protein tether to touch perception 2A second hydrocarbon boom threatens the Peruvian Amazon 2A second hydrocarbon boom threatens the Peruvian Amazon 3Stevens and TNO to collaborate on maritime security 2
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... against Nonmuscle Myosin II Heavy Chain ... in TBS + 0.03% Thimerosal) This ... SDVNETQPPQSE corresponding to the C-terminus of ... (MHC-B) This antibody is effective in ...
... reduced and non-reduced forms. It does not react ... XII. Factor XIII is a Beta-globulin found in ... XIII-A is the catalytic subunit and is a ... in plasma as an Alpha2Beta2 heterodimer (M.W. 320kDa); ...
... is a fully integrated system for fluorescent ... that deliver excellent quality microarray images. The ... microarray scanner that is based on patented ... rejection and spatial resolution. The DNAscope V ...
Biology Products: